Get started
Author

Gonzalo R. Sequeira

Observed names: G Sequeira, G. Sequeira, Gonzalo R Sequeira, Gonzalo Ricardo Sequeira, Gonzalo Sequeira, Sequeira, Gonzalo Ricardo
Observed institutions: University of North Carolina at Chapel Hill, Consejo Nacional de Investigaciones Científicas y Técnicas, University of California San Diego, Hospital Dr Arturo Oñativia, National Cancer Institute, Centro Científico Tecnológico Patagónico, Center for Cancer Research, Magdalena Villegas de Martínez el Hospital, Instituto Nacional del Cáncer, Moores Cancer Center, UNC Lineberger Comprehensive Cancer Center, Experimental Medicine and Biology Institute
OpenAlex ID: A5029302248
FGF2 induces breast cancer growth through ligand‐independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences
2019 · Sebastián Giulianelli, Marina Riggio, et al. · International Journal of Cancer · 67
PDF
Action of hexachlorobenzene on tumor growth and metastasis in different experimental models
2013 · Carolina Andrea Pontillo, Paola Rojas, et al. · Toxicology and Applied Pharmacology · 67
Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness
2016 · Paola A. Rojas, María May, et al. · JNCI Journal of the National Cancer Institute · 66
PDF
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA / PRB ratio via AIB 1 or SMRT recruitment to the CCND 1 and MYC promoters
2014 · Victoria Wargon, Marina Riggio, et al. · International Journal of Cancer · 46
PDF
Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2020 · Gonzalo R. Sequeira, Ana Sahores, et al. · Cancer Research · 38
PDF
Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer
2018 · Ana Sahores, Virginia Figueroa, et al. · Hormones and Cancer · 23
PDF
Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
2017 · Ana Sahores, María May, et al. · Current Cancer Drug Targets · 21
PDF
Isoform specificity of progesterone receptor antibodies
2017 · Victoria Fabris, María F Abascal, et al. · The Journal of Pathology Clinical Research · 20
PDF
The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer
2014 · Gonzalo Sequeira, Silvia I Vanzulli, et al. · Oncotarget · 19
PDF
Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1
2021 · María Florencia Abascal, Andrés Elia, et al. · International Journal of Cancer · 15
PDGFB as a vascular normalization agent in an ovarian cancer model treated with a gamma‐secretase inhibitor
2017 · Maria C. Pazos, Gonzalo Sequeira, et al. · Journal of Cellular Physiology · 6
PDF
Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country
2025 · Gabriela Pataccini, Andrés Elia, et al. · Scientific Reports · 4
PDF
Abstract P2-05-27: The ratio of progesterone receptor isoform A to B determines the effect of antiprogestins on preclinical models of breast cancer metastasis
2016 · C Lanari, M Alvarez, et al. · Cancer Research · 1
Introduction to Digital Pathology for Histological Imaging Analysis in Oncology: Practical Experiences
2026 · Emilia Escalona, Claudia Vejar, et al. · International Journal of Morphology
Correction: The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer
2026 · Gonzalo Sequeira, Silvia I Vanzulli, et al. · Oncotarget
PDF
Data from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Supplementary Data from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Figure S2 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Figure S4 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Figure S3 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Supplementary Table S1-S5 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Figure S1 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Figure S5 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Supplementary Data from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Figure S1 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
2023 · Gonzalo R. Sequeira, Ana Sahores, et al.
Works count: 40
Citation count: 392
H-index: 10
I10-index: 10
Year
Topic
Type